Form 4: Coya Therapeutics Director Acquires Stock Options

Coya Therapeutics, Inc. director Mark H. Pavao acquired 10,000 stock options with an exercise price of $4.53, vesting over one year.

Summary

• Mark H. Pavao, a Director at Coya Therapeutics, Inc., acquired 10,000 stock options on April 9, 2026.
• The options have an exercise price of $4.53 per share.
• These options are subject to continuous service and will vest 100% on the first anniversary of the grant date, April 9, 2036.
• The underlying securities are 10,000 shares of Common Stock, par value $0.0001 per share.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard compensation mechanism for a director rather than a significant new strategic development or financial performance indicator.

Positives

• Director Mark H. Pavao's acquisition of stock options indicates confidence in the company's future prospects.
• The vesting schedule over one year aligns management incentives with long-term company performance.

Future Outlook

The acquisition of stock options by a director suggests a positive outlook on the company's future value, as the options are only valuable if the stock price increases.

Industry Context

StockSavvy.ai notes that insider stock option grants are common in the biotechnology sector as a means to attract and retain key talent and align their interests with shareholders, especially for early-stage companies like Coya Therapeutics.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive signal of management confidence, but it also represents potential future dilution if exercised.

Key Dates

Keywords

stock options, insider trading, Coya Therapeutics, COYA, director compensation, equity award